Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PNMT | P11086 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026682 | 0.94 | IGF1R (0.67) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL8905783 | 0.92 | IGF1R (0.65) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL7008253 | 0.92 | IGF1R (0.65) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL10609252 | 0.92 | IGF1R (0.65) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL908524 | 0.86 | PNMT (0.61) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL1568422 | 0.82 | IGF1R (0.44) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL82284 | 0.82 | IGF1R (0.44) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL81132 | 0.82 | IGF1R (0.44) | IGF1RALOX15PNMTTAAR1ALDH1A1 | |
| SCHEMBL80687 | 0.82 | IGF1R (0.44) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL4023057 | 0.81 | SIGMAR1 (0.60) | IGF1RALOX15PNMTTAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230063230-A1 | NURR1 RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| CN-113692276-A | NURR1 receptor modulators | 加利福尼亚大学董事会 | 2021-11-23 | — | — | CN | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3201181-B1 | SPHINGOSINE KINASE INHIBITORS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| EP-0162208-B1 | NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4683234-A | HYPOTENSIVE AGENTS, ANTI-ANGINA | SUNTORY LIMITED (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0162208-A2 | Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1985-11-27 | — | — | EP | disclosed |
| EP-0025192-B1 | SUBSTITUTED OXIRANE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-05-11 | — | — | EP | disclosed |
| US-4324796-A | HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-04-13 | — | — | US | disclosed |
| EP-0025192-A2 | Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-03-18 | — | — | EP | disclosed |
| EP-0018144-A1 | A process for the preparation of substituted 2-aminopyrazines | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| EP-0017494-A2 | Hydroxyimino-substituted aminoacetonitrile intermediates and their preparation | ELI LILLY AND COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | IGF1R 1411/4885ALOX15 517/4885PNMT 1078/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | IGF1R 1411/4885ALOX15 517/4885PNMT 1078/4885 |
| US-20230063230-A1 | NURR1 RECEPTOR MODULATORS | NR2E3, NR4A2, NR0B1 | IGF1R 242/4885ALOX15 2491/4885PNMT 307/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | IGF1R 1411/4885ALOX15 517/4885PNMT 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.